Two RegeneRx cardiac-related patents receive notice of allowance in Australia, Mexico

RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") announced today that the Company has been notified that two cardiac-related patents will be allowed in Australia and Mexico.

The Australian patent is for the treatment or prevention of damage due to heart failure and will expire in July, 2026.

The Mexican patent is for the treatment or prevention of damage caused by increased blood flow in the myocardium, commonly called reperfusion injury. It will expire in January, 2026.

RegeneRx has similar patents pending in numerous other countries, including in the U.S., Asia and Europe.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post